GLP-1 medications continue to drive significant growth across pharmacy, telehealth, and medical-aesthetics businesses. They are also attracting increasing scrutiny from regulators, payors, manufacturers, and plaintiffs’ attorneys.

For businesses involved in prescribing, dispensing, compounding, marketing, or sourcing GLP-1 medications, compliance risk is no longer limited to whether an individual prescription is valid. Regulators are examining the entire business ecosystem: how patients are acquired, what claims are made, where medication is sourced, how prescribing decisions are reached, and whether compounded products satisfy applicable federal and state legal requirements.

5 Key Areas Healthcare Operations Must Audit

Pharmacy owners, med-spa operators, and telehealth executives should systematically evaluate five high-risk areas in their GLP-1 programs:

1. Advertising & Patient-Facing Claims

Scrutiny around GLP-1 marketing has expanded rapidly. Websites, social media campaigns, paid ads, patient intake workflows, and influencer promotions must be audited for claims regarding weight loss, safety, efficacy, bioequivalence, and availability. Avoid phrases suggesting a compounded product is identical, equivalent, or interchangeable with an FDA-approved drug. Broad claims like “safe,” “FDA approved,” “same active ingredient,” “clinically proven,” or guaranteed weight-loss results create immediate exposure if they do not accurately describe the specific product or service offered. Disclaimers buried in footers do not override the overall commercial impression created by the advertisement.

2. Supply Chain & Sourcing

Organizations must trace the precise origin of their medications and document the complete chain of distribution. This requires reviewing relationships among the prescriber, pharmacy, wholesaler, outsourcing facility, manufacturer, and any intermediary involved in sourcing. Pharmacies and clinics must verify that suppliers hold appropriate licensure for the exact transactions conducted. A low price, rapid turnaround, or supplier assurances of “pharmaceutical grade” ingredients never replace independent legal and regulatory due diligence.

3. 503A Compounding Compliance

For pharmacies compounding under Section 503A of the FD&C Act, GLP-1 activity requires rigorous oversight. Compounding practices must satisfy patient-specific prescription, ingredient, documentation, and statutory standards. The regulatory baseline shifts depending on whether an FDA-approved drug is commercially available or listed on an official shortage list. Programs developed during drug shortages cannot assume that initial operational models remain permissible once commercial availability changes.

4. Prescriber & Telehealth Relationships

Telehealth platforms and aesthetic medical practices must ensure clinical decision-making remains fully independent from commercial performance goals. Operators should review employment contracts, professional fee structures, and clinical protocols. An operational model can generate significant regulatory exposure even if individual prescriptions appear clinically justified on paper.

5. Financial Flow & Fee Structures

GLP-1 programs frequently involve multi-party transactions where funds are split among a platform, medical practice, pharmacy, marketing agency, and management company. These structures trigger complex questions regarding fee-splitting, referral fees, pharmacy steering, percentage-based compensation, and state or federal anti-kickback laws. Organizations must demonstrate that compensation represents fair market value for legitimate, necessary services rather than payment tied to the volume or value of referrals or prescriptions.

Proactive Compliance Strategy

If your business is involved in prescribing, compounding, dispensing, sourcing, or marketing GLP-1 medications, auditing your operational model proactively is far more cost-effective than responding to a regulatory investigation, payor audit, or enforcement action.

At MDRXLaw, we offer a fixed-scope GLP-1 compliance review tailored for pharmacies, med spas, and telehealth companies. Our review evaluates patient-facing advertising, supply chain sourcing, vendor agreements, and operational risk, delivering a clear assessment of issues that require remediation or clarification. To learn more about our fixed-fee GLP-1 compliance review, contact our healthcare team at 212.668.0200 or via email at info@mdrxlaw.com.